Compare NCEL & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCEL | MBAI |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.6M |
| IPO Year | N/A | N/A |
| Metric | NCEL | MBAI |
|---|---|---|
| Price | $2.64 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 186.8K | ★ 7.2M |
| Earning Date | 12-01-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $0.59 |
| 52 Week High | $7.64 | $3.92 |
| Indicator | NCEL | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 45.20 |
| Support Level | $2.40 | $1.31 |
| Resistance Level | $2.86 | $1.58 |
| Average True Range (ATR) | 0.24 | 0.44 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 38.55 | 8.24 |
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.